Linked Life Data

3073868

Source:http://linkedlifedata.com/resource/pubmed/id/3073868

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-7-10
pubmed:abstractText
The aim of this study was to evaluate the efficacy of human lymphoblastoid interferon (Wellferon) in the treatment of chronic hepatitis B virus (HBV) infection. To date 70 patients have entered the study, 33 randomized to receive interferon at doses of 5 MU/m2 i.m. daily for the first 4 weeks and three times weekly for 5 months thereafter and 31 acted as controls. Seventy-nine per cent of the treated group permanently cleared HBV DNA compared with 48% of the control group (p = 0.01): 69% of the treated patients and 38% of the controls who eliminated HBV DNA cleared HBeAg, HBeAb (p = 0.02). Twenty-four per cent of the treated patients and 3% (p = 0.01) of the control group had clearance of HBsAg and seroconversion to HBsAb. From these results it was concluded that interferon had a therapeutic effect on Italian heterosexual patients with chronic hepatitis B viral replication.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0392-906X
pubmed:author
pubmed:issnType
Print
pubmed:volume
7 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
12-4
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Treatment of chronic hepatitis B with human lymphoblastoid interferon: results of a controlled trial.
pubmed:affiliation
Clinica Medica e Gastroenterologia, Università di Bologna, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial